Hopp til hovedinnhold

Neglesopp

Neglesopp er en kronisk og hyppig forekommende tilstand som sjelden gir alvorlige symptomer. Forekomsten er økt ved høyere alder, hos idrettsfolk, hos personer som bruker tett fottøy, og hos immunsvekkede pasienter.

Sist revidert:

QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/hud/neglelidelser/neglesopp/ 

Hva er neglesopp?

Årsak

Diagnostikk

Behandling

Prognose

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Neglesopp. Referanselisten for dette dokumentet vises nedenfor.

  1. Westerberg DP, Voyack MJ. Onychomycosis: current trends in diagnosis and treatment. Am Fam Physician 2013; 88: 762-70. American Family Physician 
  2. Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol 2003;149(suppl 65):1-4.
  3. Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010;35(5):497–519.
  4. Hartman TC, van Rijswijk E. Fungal nail infection. BMJ 2008; 337: a429. PubMed 
  5. Austad J, Gjersvik PJ. Behandling av neglesopp. Tidsskr Nor Lægeforen 2001; 121: 606-7. Tidsskrift for Den norske legeforening 
  6. Tosti A. Onychomycosis clinical presentation. Medscape, last updated Jul 13, 2017. emedicine.medscape.com 
  7. Garcia-Doval I, Cabo F, Monteagudo B, et al. Clinical diagnosis of onychomycosis is possible in some patients: cross-sectional diagnostic study and development of a diagnostic rule. Br J Dermatol 2010; 163: 743-51. PubMed 
  8. Walberg M, Mørk C, Sandven P, et al. 18S rDNA polymerase chain reaction and sequencing in onychomycosis diagnostics. Acta Derm Venereol 2006; 86: 223-6. PubMed 
  9. Alberhasky RC. Laboratory diagnosis of onychomycosis. Clin Podiatr Med Surg. 2004;21(4):565–578.
  10. Statens legemiddelverk. Terapianbefaling: Behandling av dermatomykoser. Nytt om legemidler 2005; 28 (2): 28-33.
  11. Barr KL. Dermatophyte infections. BestPractice, last updated Aug 01, 2013 .
  12. Becker C, Bershow A. Lasers and photodynamic therapy in the treatment of onychomycosis: a review of the literature. Dermatol Online J 2013. pmid:24050286 PubMed 
  13. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004; 150: 537-44. PubMed 
  14. Kreijkamp-Kaspers S, Hawke KL, van Driel ML. Oral medications to treat toenail fungal infections. JAMA Clinicla Evidence Synopsis. JAMA 2018; 319: 397-8. pmid:29362778 PubMed 
  15. de Sá DC, Lamas AP, Tosti A. Oral therapy for onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014 ;15(1):17-36. doi: 10.1007/s40257-013-0056-2.
  16. Piraccini BM, Sisti A, Tosti A. Long-term follow up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agentS. J Am Acad Dermatol 2010; 62: 411-4. PubMed 
  17. Friedlander SF, Chan YC, Chan YH, Eichenfield LF. Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy. Pediatr Dermatol 2013; 30: 316-22. pmid:23278851 PubMed 
  18. Baran R, Tosti A, Hartmane I, et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol 2009; 23: 773-81. pmid:PMID: 19453778 PubMed 
  19. Iorizzo M, Hartmane I, Derveniece A, Mikazans I. Ciclopirox 8% HPCH nail laquer inthe treatment of mild-to-moderate onychomycosis: A randomized, double.blind amorolfine controlled study using a blinded evaluator. Skin Appedndage Disord 2015; 1: 134-40. doi:10.1159/000441569 DOI 
  20. Paul C, Coustou D, Lahfa M, et al. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.. Dermatology 2013; 227 (2): 157-64. pmid:24051622 PubMed 
  21. Eisman S, Sinclair R. Fungal nail infection: diagnosis and management. BMJ. 2014 Mar 24;348:g1800. doi: 10.1136/bmj.g1800. DOI 
  22. Gupta AK, Simpson FC. New pharmacotherapy for the treatment of onychomycosis: an update. Expert Opin Pharmacother 2015; 16: 227-36. pmid:25522979 PubMed 
  23. Barot BS, Parejiya PB, Patel HK, et al. Drug delivery to the nail: therapeutic options and challenges for onychomycosis. Crit Rev Ther Drug Carrier Syst 2014; 31: 459-94. pmid:Crit Rev Ther Drug Carrier Syst
  24. Ma W, Si C, Kasyanju Carrero LM, et al. Laser treatment for onychomycosis: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(48):e17948. PubMed 
  25. Goldstein AO, Bhatia N. Onychomycosis: Management. UpToDate, last updated Nov 20, 2020. UpToDate 
  26. Sotiriou E, Koussidou-Eremonti T, Chaidemenos G, et al. Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: Preliminary results of a single-centre open trial. Acta Derm Venereol 2010; 90: 216. pmid:20169321 PubMed 
  27. De Cuyper C, Hindryckx PH. Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol 1999; 141: 15-20. PubMed 

Referanser

  1. RELIS - spm. 2310 - RELIS database 2010. Dokumentasjon av Nalox mot neglesopp og neglepsoriasis.